Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 24
Filtrer
1.
Life Sci ; 271: 119198, 2021 Apr 15.
Article de Anglais | MEDLINE | ID: mdl-33577857

RÉSUMÉ

The aim of this study was to evaluate whether high levels of exogenous testosterone (T) interfere in prostate morphogenesis. Pregnant females were exposed to subcutaneous injections of T cypionate (500 µg/animal) at gestational days 20 and 22. Male and female pups were euthanized at postnatal days 1 and 15. 15-day-old males had only fibroblast growth factor 10 (FGF10) immunostaining and nuclear form factor altered by the treatment, whereas treated females (T1 and T15) had almost all analyzed parameters changed. T1 females showed an increased anogenital distance (AGD), whereas T15 females had both AGD and ovary weight increased. T1 females had a higher number of epithelial buds emerging from the urethral and vaginal epithelium. We observed ectopic prostatic tissue surrounding the vagina in both T1 and T15 females. Moreover, the ectopic acini of T15 females showed delayed luminal formation, and there was a thickening of the periacinar smooth muscle layer (SML). Finally, FGF10 immunostaining intensity decreased in both T15 male and female prostates. Indeed, Sonic hedgehog (Shh) was upregulated in T15 female prostates, whereas no difference was observed between the male groups. These data showed that exogenous T changed the nuclear morphology of prostate epithelial cells in both males and females. Surprisingly, smooth muscle hyperplasia was also observed in the ectopic female prostate. Moreover, T downregulated FGF10 in both male and female prostates. Interestingly, the results suggest that FGF10 downregulation is mediated by the upregulation of Shh in females. In conclusion, exogenous T disrupts prostate development, particularly, affecting, the female.


Sujet(s)
Épithélium/métabolisme , Facteur de croissance fibroblastique de type 10/biosynthèse , Protéines Hedgehog/biosynthèse , Muscles lisses/métabolisme , Effets différés de l'exposition prénatale à des facteurs de risque/métabolisme , Prostate/métabolisme , Testostérone/toxicité , Animaux , Animaux nouveau-nés , Épithélium/effets des médicaments et des substances chimiques , Épithélium/anatomopathologie , Femelle , Facteur de croissance fibroblastique de type 10/génétique , Régulation de l'expression des gènes au cours du développement , Gerbillinae , Protéines Hedgehog/génétique , Mâle , Muscles lisses/cytologie , Muscles lisses/effets des médicaments et des substances chimiques , Grossesse , Effets différés de l'exposition prénatale à des facteurs de risque/induit chimiquement , Prostate/effets des médicaments et des substances chimiques , Prostate/anatomopathologie
2.
Mol Ther ; 27(6): 1101-1113, 2019 06 05.
Article de Anglais | MEDLINE | ID: mdl-31005598

RÉSUMÉ

Most cases of sensorineural deafness are caused by degeneration of hair cells. Although stem/progenitor cell therapy is becoming a promising treatment strategy in a variety of organ systems, cell engraftment in the adult mammalian cochlea has not yet been demonstrated. In this study, we generated human otic progenitor cells (hOPCs) from induced pluripotent stem cells (iPSCs) in vitro and identified these cells by the expression of known otic markers. We showed successful cell transplantation of iPSC-derived-hOPCs in an in vivo adult guinea pig model of ototoxicity. The delivered hOPCs migrated throughout the cochlea, engrafted in non-sensory regions, and survived up to 4 weeks post-transplantation. Some of the engrafted hOPCs responded to environmental cues within the cochlear sensory epithelium and displayed molecular features of early sensory differentiation. We confirmed these results with hair cell progenitors derived from Atoh1-GFP mice as donor cells. These mouse otic progenitors transplanted using the same in vivo delivery system migrated into damaged cochlear sensory epithelium and adopted a partial sensory cell fate. This is the first report of the survival and differentiation of hOPCs in ototoxic-injured mature cochlear epithelium, and it should stimulate further research into cell-based therapies for treatment of deafness.


Sujet(s)
Augmentation de la taille cellulaire , Cellules ciliées auditives/effets des médicaments et des substances chimiques , Perte d'audition/chirurgie , Cellules souches pluripotentes induites/métabolisme , Cellules souches pluripotentes induites/transplantation , Ototoxicité/chirurgie , Transplantation de cellules souches/méthodes , Amikacine/effets indésirables , Amikacine/pharmacologie , Animaux , Seuil auditif/effets des médicaments et des substances chimiques , Différenciation cellulaire/effets des médicaments et des substances chimiques , Mouvement cellulaire/effets des médicaments et des substances chimiques , Ciclosporine/pharmacologie , Modèles animaux de maladie humaine , Facteur de croissance fibroblastique de type 10/pharmacologie , Facteur de croissance fibroblastique de type 3/pharmacologie , Cochons d'Inde , Cellules ciliées auditives/immunologie , Cellules ciliées auditives/métabolisme , Perte d'audition/induit chimiquement , Humains , Immunosuppresseurs/pharmacologie , Cellules souches pluripotentes induites/immunologie , Donneur vivant
3.
J Cell Physiol ; 234(5): 6886-6897, 2019 05.
Article de Anglais | MEDLINE | ID: mdl-30362535

RÉSUMÉ

Androgens induce rat prostate induction from the urogenital sinus epithelium at embryonic day 17.5. Subsequent morphogenesis, including epithelial cord growth, branching, and canalization, results from concerted paracrine interactions with the stroma. A significant number of paracrine factors bind heparan sulfate (HS). We hypothesized that interfering with overall sulfation could disrupt the signaling mediated by HS-binding factors and that the undersulfated environment would allow investigation of individual exogenous morphogens. First, we investigated whether acinar morphogenesis involved HS-proteoglycan expression and found that syndecans 1 and 3 were upregulated in RWPE1 cells in the transition from two- to three-dimensional (3D) Matrigel, capable of promoting spheroid formation. We then investigated whether sodium chlorate, a general sulfation inhibitor, interfered with spheroid formation by RWPE1 cells and acinar morphogenesis in ex vivo ventral prostate (VP) organ culture. As expected, treatment with sodium chlorate inhibited spheroid formation by RWPE1 cells in 3D culture. Chlorate also inhibited ex vivo VP epithelial branching and canalization, resulting in long branchless epithelial structures. We then investigated whether the HS-binding factors, FGF10, TGFß1, and SDF1, could reverse the effect of sodium chlorate. Although no effect was seen in the FGF10- and TGFß1-treated samples, SDF1 promoted epithelial canalization in the low sulfated environment, highlighting its specific role in lumen formation. Altogether, the results show that sodium chlorate perturbed prostate morphogenesis and allowed investigation of factors involved in branching and/or canalization, implicating SDF1 signaling in epithelial canalization.


Sujet(s)
Chimiokine CXCL12/métabolisme , Cellules épithéliales/métabolisme , Morphogenèse/physiologie , Prostate/métabolisme , Prostate/physiologie , Animaux , Lignée cellulaire , Collagène/métabolisme , Association médicamenteuse , Cellules épithéliales/physiologie , Épithélium/métabolisme , Épithélium/physiologie , Facteur de croissance fibroblastique de type 10/métabolisme , Régulation de l'expression des gènes au cours du développement/physiologie , Protéoglycanes à sulfate d'héparane/métabolisme , Héparitine sulfate/métabolisme , Humains , Laminine/métabolisme , Mâle , Techniques de culture d'organes/méthodes , Organogenèse/physiologie , Protéoglycanes/métabolisme , Rats , Rat Wistar , Transduction du signal/physiologie , Facteur de croissance transformant bêta-1/métabolisme
4.
Theriogenology ; 102: 190-198, 2017 Oct 15.
Article de Anglais | MEDLINE | ID: mdl-28826105

RÉSUMÉ

In an attempt to improve in vitro embryo production, we investigated the effect of FGF10 and 0.1 mM of cilostamide, cAMP modulator, during in vitro prematuration (PIVM) and in vitro maturation (IVM) on the developmental capacity of bovine oocytes. Five treatments (T) were used as follows: T1) IVM (control): COCs were matured for 22 h; T2) PIVM/IVM: COCs were submitted to 22 h of PIVM and 22 h of IVM; T3) PIVM + FGF10/IVM: COCs were submitted to PIVM for 22 h in the presence of FGF10 and matured for 22 h; T4) PIVM/IVM + FGF10: COCs were submitted to PIVM for 22 h and matured for 22 h in the presence of FGF10; and T5) PIVM + FGF10/IVM + FGF10: COCs were submitted to 22 h of PIVM and 22 h of IVM, both in the presence of FGF10. COCs were evaluated for CC expansion and nucleus configuration at 0 h, 22 h of PIVM and 22 h after IVM. At those time points, CCs were used for expression analysis of PTGS2, TNFAIP6, PTX3, HAS2, CASP8, CASP3, SLC2A1, SLC2A3 and FGFR2 genes. Then, embryo production was evaluated on D2 for cleavage and at D6, D7 and D8 for embryo development. Embryo quality was measured by the speed of development and by expression of KRT8, PLAC8, CD9, PAG2, PAG2, HSPB1, MSH6 genes. The percentage of COC that remained at GV after 22 h PIVM was lower (P < 0.05) in the treated group than in the control group, regardless of the addition of FGF10. Nevertheless at 22 h of maturation, none of the treatments affected the final rate of MII oocytes. No expansion of CCs was observed during the PIVM period. After 22 h of maturation expansion was similar (P > 0.05) for all groups but they all had lower expansion (P < 0.05) than control group. Except for PTGS2 and SLC2A1 which were unchanged during PIVM, all other genes changed their expression during PIVM. When we evaluated the changes in gene expression during IVM on the different groups, we noted a change in the expression of four genes (PTGS2, CASP8, PTX3 and TNFAIP6). No differences (P > 0.05) in the cleavage and blastocyst rates at D6 were observed among treatment groups. However, the blastocyst rates at D7 were lower (P < 0.05) than the control groups in which FGF10 was present either during PIVM or during IVM. When the speed of embryo development was evaluated on D7, embryos from groups PIVM-IVM and PIVM - IVM + FGF10 developed faster than the other groups. However, at D8, the hatching rate was similar (P > 0.05) for all groups. Of all the analysed genes, only PLAC8 was shown to be overexpressed in PIVM/IVM + FGF10, and MSH6 was less expressed (P < 0.05) in PIVM + FGF10/IVM + FGF10 group when compared with the control. According to these findings, the PIVM of COCs in the presence of FGF10 affected the molecular profile and the expansion of CCs without affecting the nuclear maturation and embryo production rates. Although the presence of FGF10 changed the expression of genes related to embryo quality it did not show a great impact when added either or both during PIVM and IVM.


Sujet(s)
Bovins , Facteur de croissance fibroblastique de type 10/pharmacologie , Techniques de maturation in vitro des ovocytes/médecine vétérinaire , Ovocytes/effets des médicaments et des substances chimiques , Animaux , Cellules du cumulus , Techniques de culture d'embryons , Développement embryonnaire , Femelle
5.
Reprod Toxicol ; 73: 30-40, 2017 10.
Article de Anglais | MEDLINE | ID: mdl-28768143

RÉSUMÉ

We employed histological techniques to assess the effects of intrauterine exposure to different dosages of E2 on male and female Mongolian gerbils on the postnatal development of the prostate. E2 promotes alterations this gland branches in the female, but not in males, even at low dosage, at higher dosages, acini of altered aspect are verified in the male and female prostate, as well as a decrease in branching number, reduced cell proliferation and staining for FGF10, simultaneously to the increased labelling for TGFß1, which may account for alterations on branching of the prostate. The sensitivity of the female prostate to intrauterine exposure to E2, which can reflect the E2 dependence of female prostate development. This becomes alarming in view of the occurrence of prostate in female of several mammals and including women, and the possibility that low E2 dosage exposures considered safe to males provoke developmental alterations in female prostate.


Sujet(s)
Oestradiol/toxicité , Oestrogènes/toxicité , Effets différés de l'exposition prénatale à des facteurs de risque , Prostate/effets des médicaments et des substances chimiques , Animaux , Antigènes CD34/métabolisme , Oestradiol/sang , Récepteur alpha des oestrogènes/métabolisme , Récepteur bêta des oestrogènes/métabolisme , Oestrogènes/sang , Femelle , Facteur de croissance fibroblastique de type 10/métabolisme , Gerbillinae , Mâle , Échange foetomaternel , Grossesse , Prostate/métabolisme , Prostate/anatomopathologie , Récepteurs aux androgènes/métabolisme , Facteur de croissance transformant bêta-1/métabolisme
6.
Am J Orthod Dentofacial Orthop ; 151(4): 700-707, 2017 Apr.
Article de Anglais | MEDLINE | ID: mdl-28364893

RÉSUMÉ

INTRODUCTION: Our goal was to verify the association between candidate polymorphisms and skeletal Class III malocclusion in a well-characterized homogeneous sample set. METHODS: Thirty-five single-nucleotide polymorphisms were studied from 10 candidate loci in 54 Class III subjects and 120 controls. Skeletal Class III characteristics included ANB angle less than 0°, SNB angle greater than 83° (mandibular prognathism), SNA angle less than 79° (maxillary deficiency), Class III molar relationship, and negative overjet. Inclusion criteria for the controls were ANB angle between 0° and 4°, Class I molar relationship, and normal overjet. Chi-square and Fisher exact tests and principal component (PC) analysis were used to determine overrepresentation of marker alleles with alpha of 0.05. Odds ratios and 95% confidence intervals were calculated. RESULTS: MYO1H (rs10850110 AG) (P = 0.001) with PC2 and between FGF10 (rs593307 A

Sujet(s)
Malocclusion de classe III/génétique , Polymorphisme de nucléotide simple/génétique , Protéines de transport/génétique , Protéines de transport/physiologie , Études cas-témoins , Femelle , Facteur de croissance fibroblastique de type 10/génétique , Facteur de croissance fibroblastique de type 10/physiologie , Études d'associations génétiques , Humains , Mâle , Myosine de type I/génétique , Myosine de type I/physiologie , Polymorphisme de nucléotide simple/physiologie , Jeune adulte
7.
J Assist Reprod Genet ; 34(3): 383-390, 2017 Mar.
Article de Anglais | MEDLINE | ID: mdl-28000057

RÉSUMÉ

PURPOSE: In an attempt to improve in vitro embryo production, we investigated the effect of fibroblast growth factor 10 (FGF10) during in vitro maturation on the developmental capacity of bovine oocytes. MATERIAL AND METHODS: Cumulus-oocyte complexes (COCs) were aspirated from follicles of 3-8 mm diameter. After selection, the COCs were matured in medium with or without 0.5 ng/mL of FGF10. The effect of FGF10 during in vitro maturation (IVM) on nuclear maturation kinetics and expansion of the cumulus cells was investigated. Oocyte competence was assessed by the production and development speed of embryos and the relative expression of genes associated with embryo quality. RESULTS: FGF10 delayed the resumption of meiosis from 8 h onwards, but did not affect the percentage of oocytes reaching metaphase II, nor did it increase cumulus expansion at 22 h of maturation. We found no difference between treatments regarding embryo production, developmental speed, and gene expression. CONCLUSION: In conclusion, the presence of FGF10 during IVM had no effect on embryo production, developmental speed, and gene expression.


Sujet(s)
Développement embryonnaire/génétique , Facteur de croissance fibroblastique de type 10/biosynthèse , Techniques de maturation in vitro des ovocytes , Ovocytes/croissance et développement , Animaux , Blastocyste/métabolisme , Bovins , Cellules du cumulus/métabolisme , Techniques de culture d'embryons , Femelle , Régulation de l'expression des gènes au cours du développement , Méiose/génétique , Ovocytes/métabolisme
8.
Reprod Fertil Dev ; 29(2): 234-243, 2017 Feb.
Article de Anglais | MEDLINE | ID: mdl-26194863

RÉSUMÉ

There is evidence that regulation of follicle selection in cattle involves locally produced growth factors. In the present study, we investigated the expression of members of the fibroblast growth factor (FGF) 7 family during follicle deviation. The largest and second largest follicles were recovered during the second day of a synchronised follicle wave and the future dominant and future subordinate follicles were identified based on diameter and cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1) mRNA levels in granulosa cells. Theca cells of the future dominant follicle contained less mRNA encoding FGF7 and FGF10 compared with those from the future subordinate follicle 2.5 days after ovulation, before a significant difference between the diameters of the future dominant and future subordinate follicles could be observed, but FGF22 mRNA levels did not change. Levels of mRNA encoding FGF receptors FGFR1B and FGFR2B in theca and granulosa cells, respectively, were lower in the future dominant follicle compared with the future subordinate follicle. Addition of FGF10 to granulosa cells in vitro significantly decreased oestradiol secretion, as well as CYP19A1, FSH receptor (FSHR) and insulin-like growth factor 1 receptor (IGF1R) mRNA abundance, whereas FGF22 had no effect. We conclude that FGF10 and FGFR2B expression is increased in the future subordinate follicle before morphological deviation, which may contribute to follicle selection.


Sujet(s)
Facteur de croissance fibroblastique de type 10/métabolisme , Follicule ovarique/métabolisme , Ovaire/métabolisme , Ovulation/métabolisme , Récepteur FGFR2/métabolisme , Animaux , Bovins , Femelle , Facteur de croissance fibroblastique de type 10/pharmacologie , Hormone folliculostimulante/métabolisme , Cellules de la granulosa/effets des médicaments et des substances chimiques , Cellules de la granulosa/métabolisme , Follicule ovarique/effets des médicaments et des substances chimiques , Ovaire/effets des médicaments et des substances chimiques , Ovulation/effets des médicaments et des substances chimiques , Récepteur FGFR1/métabolisme , Récepteur FSH/métabolisme , Cellules thécales/effets des médicaments et des substances chimiques , Cellules thécales/métabolisme
9.
Adv Exp Med Biol ; 913: 193-206, 2016.
Article de Anglais | MEDLINE | ID: mdl-27796889

RÉSUMÉ

The telocytes have recently been described in the prostate gland. In mature gland, they exist in close association with the acini and their telopodes form networks whose functions remain unclear. In this chapter, our group gives a brief introduction to telocytes and explores the history that led to such a concept and then discusses hypotheses and presents new evidences about the roles exerted by telocytes in the prostate. First is given emphasis on the role that these cells possibly play in paracrine signaling employed in the differentiation of smooth muscle periacinar are then discussed other roles potentially performed by telocytes in the prostate, such as the organizational, where these cells would act in order to delimit stromal microenvironments, thereby assisting the differentiation of the prostatic anatomical components. In addition, the pacemaker function of smooth muscle cells contraction, as evidenced by the presence of caveolae and gap-type junction and, finally, the role of telocytes in prostate remodeling and the possible action as adult progenitor cells. Generally speaking, the chapter reaffirms the existence of telocytes as distinct cells of other stromal cells and the importance of this new cell type for normal metabolism and prostate development.


Sujet(s)
Tissu conjonctif/métabolisme , Fibroblastes/métabolisme , Gerbillinae/physiologie , Myocytes du muscle lisse/métabolisme , Communication paracrine/physiologie , Prostate/métabolisme , Télocytes/métabolisme , Animaux , Antigènes CD34/génétique , Antigènes CD34/métabolisme , Marqueurs biologiques/métabolisme , Différenciation cellulaire , Femelle , Facteur de croissance fibroblastique de type 10/génétique , Facteur de croissance fibroblastique de type 10/métabolisme , Fibroblastes/cytologie , Jonctions communicantes/métabolisme , Jonctions communicantes/ultrastructure , Expression des gènes , Gerbillinae/anatomie et histologie , Mâle , Myocytes du muscle lisse/cytologie , Prostate/cytologie , Facteurs sexuels , Spécificité d'espèce , Télocytes/cytologie , Facteur de croissance transformant bêta-1/génétique , Facteur de croissance transformant bêta-1/métabolisme
10.
Genet Mol Res ; 15(3)2016 Aug 26.
Article de Anglais | MEDLINE | ID: mdl-27706598

RÉSUMÉ

Development of the eyelid requires coordination of the cellular processes involved in proliferation, cell size alteration, migration, and cell death. C57BL/6J-corneal opacity (B6-Co) mice are mutant mice generated by the administration of N-ethyl-N-nitrosourea (100 mg/kg). They exhibit the eyelids open at birth phenotype, abnormal round cell shape from tightened F-actin bundles in leading edge keratinocytes at E16.5, and gradual corneal opacity with neovessels. The tip of the leading edge in B6-Co mice did not move forward, and demonstrated a sharp peak shape without obvious directionality. Analysis of the biological characteristics of B6-Co mice demonstrated that abnormal migration of keratinocytes could affect eyelid development, but proliferation and apoptosis in B6-Co mice had no effect. Mutant gene mapping and sequence analysis demonstrated that in B6-Co mice, adenosine was inserted into the untranslated regions, between 3030 and 3031, in the mRNA 3'-terminal of Fgf10. In addition, guanine 7112 was substituted by adenine in the Mtap1B mRNA, and an A2333T mutation was identified in Mtap1B. Quantitative real-time polymerase chain reaction analysis showed that expression of the Hbegf gene was significantly down-regulated in the eyelids of B6- Co mice at E16.5, compared to B6 mice. However, the expression of Rock1, Map3k1, and Jnk1 genes did not show any significant changes. Abnormal keratinocyte migration and down-regulated expression of the Hbegf gene might be associated with impaired eyelid development in B6-Co mice.


Sujet(s)
Cornée/métabolisme , Néovascularisation cornéenne/génétique , Opacité cornéenne/génétique , Paupières/métabolisme , Facteur de croissance de type EGF liant l'héparine/génétique , Kératinocytes/métabolisme , Régions 3' non traduites , Actines/génétique , Actines/métabolisme , Animaux , Mouvement cellulaire , Polarité de la cellule , Prolifération cellulaire , Forme de la cellule , Cornée/malformations , Cornée/croissance et développement , Néovascularisation cornéenne/induit chimiquement , Néovascularisation cornéenne/métabolisme , Néovascularisation cornéenne/anatomopathologie , Opacité cornéenne/induit chimiquement , Opacité cornéenne/métabolisme , Opacité cornéenne/anatomopathologie , Embryon de mammifère , 1-Éthyl-1-nitroso-urée , Paupières/malformations , Paupières/croissance et développement , Facteur de croissance fibroblastique de type 10/génétique , Facteur de croissance fibroblastique de type 10/métabolisme , Régulation de l'expression des gènes au cours du développement , Facteur de croissance de type EGF liant l'héparine/métabolisme , Kératinocytes/anatomopathologie , Souris , Souris de lignée C57BL , Protéines associées aux microtubules/génétique , Protéines associées aux microtubules/métabolisme , Mutagènes , Phénotype , Culture de cellules primaires
11.
Nat Genet ; 48(1): 12-21, 2016 Jan.
Article de Anglais | MEDLINE | ID: mdl-26618344

RÉSUMÉ

Genetic risk for breast cancer is conferred by a combination of multiple variants of small effect. To better understand how risk loci might combine, we examined whether risk-associated genes share regulatory mechanisms. We created a breast cancer gene regulatory network comprising transcription factors and groups of putative target genes (regulons) and asked whether specific regulons are enriched for genes associated with risk loci via expression quantitative trait loci (eQTLs). We identified 36 overlapping regulons that were enriched for risk loci and formed a distinct cluster within the network, suggesting shared biology. The risk transcription factors driving these regulons are frequently mutated in cancer and lie in two opposing subgroups, which relate to estrogen receptor (ER)(+) luminal A or luminal B and ER(-) basal-like cancers and to different luminal epithelial cell populations in the adult mammary gland. Our network approach provides a foundation for determining the regulatory circuits governing breast cancer, to identify targets for intervention, and is transferable to other disease settings.


Sujet(s)
Tumeurs du sein/génétique , Réseaux de régulation génique , Locus de caractère quantitatif , Facteurs de transcription/génétique , Tumeurs du sein/mortalité , Lignée cellulaire tumorale , Immunoprécipitation de la chromatine/méthodes , Analyse de regroupements , Récepteur alpha des oestrogènes/génétique , Femelle , Facteur de croissance fibroblastique de type 10/génétique , Facteur de croissance fibroblastique de type 10/métabolisme , Analyse de profil d'expression de gènes/méthodes , Prédisposition génétique à une maladie , Étude d'association pangénomique , Humains , Mutation , Reproductibilité des résultats
12.
Genet Mol Res ; 14(4): 15642-51, 2015 Dec 02.
Article de Anglais | MEDLINE | ID: mdl-26634532

RÉSUMÉ

A rat model of ventilation-induced lung injury (VILI) during anesthesia was generated to investigate the potential role and possible mechanism of interleukin-10 (IL-10) and recombinant human keratinocyte growth factor-2 (rhKGF-2) in protecting anesthetized rats against VILI. A total of 50 male SD rats were randomly divided into 5 groups (N = 10 each): control, VILI, IL-10, rhKGF-2, and IL-10 + rhKGF-2. The VILI (model) group was generated via ventilation, with a tidal volume of 20 mL/kg. Rats in the IL-10 and rhKGF-2 groups received 8 mg/kg IL-10 and 5 mg/kg rhKGF-2, respectively, prior to ventilation. The rats in the IL-10 + rhKGF-2 group received both 8 mg/kg IL-10 and 5 mg/kg rhKGF-2 72 h before ventilation. The total number of nucleated cells and neutrophils in the bronchial alveolar lavage fluid was quantified, and the pathological changes in the pulmonary tissues examined by hematoxylin and eosin staining. The transcript and protein levels of surfactant protein C (SP-C) in lung tissues were detected by real-time polymerase chain reaction and western blot analyses. The SP-C mRNA expression in both IL-10 and rhKGF-2 groups was similar to that in the VILI group. However, this was significantly elevated in the combined treatment group (P < 0.05), indicating that IL-10 and rhKGF-2 could synergistically protect the lung tissue from VILI via the enhancement of SP-C mRNA expression in lung tissues. The protein assay showed a decreased level of infiltration and activation of inflammatory cells, in addition to increased expression of SP-C, thereby confirming the efficacy of this treatment in preventing VILI during anesthesia.


Sujet(s)
Facteur de croissance fibroblastique de type 10/pharmacologie , Interleukine-10/pharmacologie , Agents protecteurs/pharmacologie , Protéines recombinantes/pharmacologie , Lésion pulmonaire induite par la ventilation mécanique/anatomopathologie , Animaux , Marqueurs biologiques , Liquide de lavage bronchoalvéolaire , Numération cellulaire , Modèles animaux de maladie humaine , Humains , Poumon/effets des médicaments et des substances chimiques , Poumon/métabolisme , Poumon/anatomopathologie , Mâle , Infiltration par les neutrophiles , Protéine C associée au surfactant pulmonaire/métabolisme , ARN messager/génétique , Rats , Lésion pulmonaire induite par la ventilation mécanique/traitement médicamenteux , Lésion pulmonaire induite par la ventilation mécanique/génétique , Lésion pulmonaire induite par la ventilation mécanique/métabolisme
13.
Anim Reprod Sci ; 152: 32-8, 2015 Jan.
Article de Anglais | MEDLINE | ID: mdl-25496673

RÉSUMÉ

A sequential medium with fibroblast growth factor-10 (FGF-10) and follicle stimulating hormone (FSH) was evaluated on the survival, ultrastructure, activation and growth rate of caprine preantral follicles submitted to long-term culture, aiming to establish an ideal in vitro culture system. Ovarian fragments were cultured for 16 days in α-MEM(+) alone or supplemented with FGF-10 and/or FSH added sequentially on different days of culture. Ovarian fragments were cultured during the first (days 0-8) and second (days 8-16) halves of the culture period, generating 10 treatments: α-MEM(+)/α-MEM(+) (cultured control), FSH/FSH, FSH/FGF-10, FSH/FSH+FGF-10, FGF-10/FGF-10, FGF-10/FSH, FGF-10/FSH+FGF-10, FSH+FGF-10/FSH+FGF-10, FSH+FGF-10/FSH and FSH+FGF-10/FGF-10. Follicle morphology, viability and ultrastructure were analyzed. The FSH/FGF-10 treatment showed a higher (P<0.05) percentage of normal follicles compared to all other treatments. In addition, follicles from the FSH/FGF-10 treatment maintained ultrastructural integrity after the culture period. After 16 days of culture, the FSH/FGF-10 and FSH/FSH treatments showed a higher percentage of activation compared to the cultured control (α-MEM(+)/α-MEM(+)). Moreover, the FSH/FGF-10 treatment promoted greater follicular and oocyte diameters compared to the fresh control. In conclusion, this study showed that a sequential medium with FSH followed by FGF-10 (FSH/FGF-10 and FSH/FSH) maintains follicular viability and ultrastructure and promotes transition from the primordial to primary stage (activation) and growth in goat preantral follicles cultured in vitro.


Sujet(s)
Facteur de croissance fibroblastique de type 10/pharmacologie , Hormone folliculostimulante/pharmacologie , Capra , Follicule ovarique/effets des médicaments et des substances chimiques , Follicule ovarique/croissance et développement , Animaux , Milieux de culture/composition chimique , Femelle , Techniques de culture de tissus/médecine vétérinaire
14.
Reprod Domest Anim ; 50(1): 84-90, 2015 Feb.
Article de Anglais | MEDLINE | ID: mdl-25495767

RÉSUMÉ

Fibroblast growth factor (FGF10) acts at the cumulus oocyte complex, increasing the expression of cumulus cell expansion-related genes and oocyte competency genes. We tested the hypothesis that addition of FGF10 to the maturation medium improves oocyte maturation, decreases the percentage of apoptotic oocytes and increases development to the blastocyst stage while increasing the relative abundance of developmentally important genes (COX2, CDX2 and PLAC8). In all experiments, oocytes were matured for 22 h in TCM-199 supplemented with 0, 2.5, 10 or 50 ng/ml FGF10. In Experiment 1, after maturation, oocytes were stained with Hoechst to evaluate meiosis progression (metaphase I, intermediary phases and extrusion of the first polar body) and submitted to the TUNEL assay to evaluate apoptosis. In Experiment 2, oocytes were fertilized and cultured to the blastocyst stage. Blastocysts were frozen for analysis of COX2, CDX2 and PLAC8 relative abundance. In Experiment 1, 2.5 ng/ml FGF10 increased (p < 0.05) the percentage of oocytes with extrusion of the first polar body (35%) compared to 0, 10 and 50 ng/ml FGF10 (21, 14 and 12%, respectively) and FGF10 decreased the percentage of oocytes that were TUNEL positive in all doses studied. In Experiment 2, there was no difference in the percentage of oocytes becoming blastocysts between treatments and control. Real-time RT-PCR showed a tendency of 50 ng/ml FGF10 to increase the relative abundance of COX2 and PLAC8 and of 10 ng/ml FGF10 to increase CDX2. In conclusion, the addition of FGF10 to the oocyte maturation medium improves oocyte maturation in vitro, decreases the percentage of apoptotic oocytes and tends to increase the relative abundance of developmentally important genes.


Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Bovins , Développement embryonnaire/effets des médicaments et des substances chimiques , Facteur de croissance fibroblastique de type 10/pharmacologie , Méiose/effets des médicaments et des substances chimiques , Ovocytes/cytologie , Animaux , Blastocyste/composition chimique , Blastocyste/physiologie , Facteurs de transcription CDX2 , Milieux de culture , Cellules du cumulus/physiologie , Cyclooxygenase 2/génétique , Techniques de culture d'embryons/médecine vétérinaire , Femelle , Fécondation in vitro/effets des médicaments et des substances chimiques , Facteur de croissance fibroblastique de type 10/administration et posologie , Gènes du développement , Protéines à homéodomaine/génétique , Méthode TUNEL , Techniques de maturation in vitro des ovocytes , Ovocytes/composition chimique , Protéines de la grossesse/génétique , ARN messager/analyse , Transactivateurs/génétique
15.
Theriogenology ; 81(9): 1268-74, 2014 Jun.
Article de Anglais | MEDLINE | ID: mdl-24650928

RÉSUMÉ

In the mammalian ovary, FGF10 is expressed in oocytes and theca cells and is a candidate for paracrine signaling to the developing granulosa cells. To gain insight into the participation of FGF10 in the regulation of fetal folliculogenesis, we assessed mRNA expression patterns of FGF10 and its receptors, FGFR1B and FGFR2B, in relation to fetal follicle dynamics and localized FGF10 protein in bovine fetal ovaries at different ages. Primordial, primary, secondary, and antral follicles were first observed on Days 75, 90, 150, and 210 of gestation, respectively. The levels of GDF9 and BMP15 mRNA, markers for primordial and primary follicles, respectively, increased during fetal ovary development in a consistent manner with fetal follicle dynamics. CYP17A1 mRNA abundance increased from Day 60 to Day 75 and then from Day 120 to Day 150, coinciding with the appearance of secondary follicles. FGF10 mRNA abundance increased from Day 90, and this increase was temporally associated with increases in FGFR1B mRNA abundance and in the population of primary follicles. In contrast, FGFR2B mRNA expression was highest on Day 60 and decreased thereafter. FGF10 protein was localized to oogonia and oocytes and surrounding granulosa cells at all fetal ages. The present data suggest a role for FGF10 in the control of fetal folliculogenesis in cattle.


Sujet(s)
Bovins/embryologie , Facteur de croissance fibroblastique de type 10/métabolisme , Régulation de l'expression des gènes au cours du développement/physiologie , Ovaire/embryologie , Animaux , Femelle , Facteur de croissance fibroblastique de type 10/génétique , Ovaire/métabolisme , Récepteur facteur croissance fibroblaste/génétique , Récepteur facteur croissance fibroblaste/métabolisme
16.
Reproduction ; 146(1): 27-35, 2013 Jul.
Article de Anglais | MEDLINE | ID: mdl-23641036

RÉSUMÉ

Oocyte-secreted factors (OSFs) regulate differentiation of cumulus cells and are of pivotal relevance for fertility. Bone morphogenetic protein 15 (BMP15) and fibroblast growth factor 10 (FGF10) are OSFs and enhance oocyte competence by unknown mechanisms. We tested the hypothesis that BMP15 and FGF10, alone or combined in the maturation medium, enhance cumulus expansion and expression of genes in the preovulatory cascade and regulate glucose metabolism favouring hyaluronic acid production in bovine cumulus-oocyte complexes (COCs). BMP15 or FGF10 increased the percentage of fully expanded COCs, but the combination did not further stimulate it. BMP15 increased cumulus cell levels of mRNA encoding a disintegrin and metalloprotease 10 (ADAM10), ADAM17, amphiregulin (AREG), and epiregulin (EREG) at 12 h of culture and of prostaglandin (PG)-endoperoxide synthase 2 (PTGS2), pentraxin 3 (PTX3) and tumor necrosis factor alpha-induced protein 6 (TNFAIP6 (TSG6)) at 22 h of culture. FGF10 did not alter the expression of epidermal growth factor-like factors but enhanced the mRNA expression of PTGS2 at 4 h, PTX3 at 12 h, and TNFAIP6 at 22 h. FGF10 and BMP15 stimulated glucose consumption by cumulus cells but did not affect lactate production or levels of mRNA encoding glycolytic enzymes phosphofructokinase and lactate dehydrogenase A. Each growth factor increased mRNA encoding glucosamine:fructose-6-PO4 transaminases, key enzymes in the hexosamine pathway leading to hyaluronic acid production, and BMP15 also stimulated hyaluronan synthase 2 (HAS2) mRNA expression. This study provides evidence that BMP15 and FGF10 stimulate expansion of in vitro-matured bovine COCs by driving glucose metabolism toward hyaluronic acid production and controlling the expression of genes in the ovulatory cascade, the first acting upon ADAM10, ADAM17, AREG, and EREG and the second on downstream genes, particularly PTGS2.


Sujet(s)
Protéine morphogénétique osseuse de type 15/physiologie , Cellules du cumulus/physiologie , Facteur de croissance fibroblastique de type 10/physiologie , Ovocytes/physiologie , Ovulation , Animaux , Bovins , Femelle , Expression des gènes , Régulation de l'expression des gènes , Glucose/métabolisme
17.
J Dent Res ; 92(2): 149-55, 2013 Feb.
Article de Anglais | MEDLINE | ID: mdl-23169889

RÉSUMÉ

It has been proposed that tooth agenesis and cancer development share common molecular pathways. We performed a cross-sectional study to investigate the epidemiological and molecular association between tooth agenesis and self-reported family history of cancer. Eighty-two individuals with tooth agenesis and 328 individuals with no birth defect were recruited from the same institution. Tooth agenesis was assessed in permanent teeth and was defined based on the age of the participants and when initial tooth formation should be radiographically visible. We also investigated the role of genes involved in dental development that have been implicated in tumorigenesis, and 14 markers in AXIN2, FGF3, FGF10, and FGFR2 were genotyped. Individuals with tooth agenesis had an increased risk of having a family history of cancer (p = 0.00006; OR = 2.7; 95% C.I., 1.6-4.4). There were associations between AXIN2, FGF3, FGF10, and FGFR2 with tooth agenesis [i.e., individuals who carried the polymorphic allele of FGFR2 (rs1219648) presented higher risk for having premolar agenesis (p = 0.02; OR = 1.8; 95% C.I., 1.1-3.0)]. In conclusion, tooth agenesis was associated with positive self-reported family history of cancer and with variants in AXIN2, FGF3, FGF10, and FGFR2. Prospective studies are needed to confirm if tooth agenesis can be used as a risk marker for cancer.


Sujet(s)
Anodontie/génétique , Tumeurs/génétique , Allèles , Anodontie/épidémiologie , Axine/génétique , Prémolaire/malformations , Brésil/épidémiologie , Tumeurs du sein/épidémiologie , Tumeurs du sein/génétique , Études cas-témoins , Études transversales , Études épidémiologiques , Femelle , Facteur de croissance fibroblastique de type 10/génétique , Facteur de croissance fibroblastique de type 3/génétique , Variation génétique/génétique , Génotype , Humains , Incisive/malformations , Mâle , Épidémiologie moléculaire , Tumeurs/épidémiologie , Odontogenèse/génétique , Polymorphisme génétique/génétique , Tumeurs de la prostate/épidémiologie , Tumeurs de la prostate/génétique , Récepteur FGFR2/génétique , Facteurs de risque , Autorapport
18.
Anim Reprod Sci ; 134(3-4): 141-9, 2012 Oct.
Article de Anglais | MEDLINE | ID: mdl-22959639

RÉSUMÉ

The number of follicles recruited in each estrous cycle has gained practical importance in artificial reproductive technology, as it determines the oocyte yield from ultrasound-guided ovum pickup for in vitro embryo production. We aimed to identify single nucleotide polymorphisms (SNPs) in bovine genes related to reproductive physiology and evaluate the association between the candidate SNPs and the number of oocytes collected from ultrasound-guided ovum pickup. We sequenced genomic segments of GDF9, FGF8, FGF10 and BMPR2 and identified seventeen SNPs in the Bos taurus and Bos indicus breeds. Two SNPs cause amino acid changes in the proteins GDF9 and FGF8. Three SNPs in GDF9, FGF8 and BMPR2 were genotyped in 217 Nelore cows (B. indicus), while two previously identified mutations in LHCGR and mitochondrial DNA (mtDNA) were genotyped in the same group. The polymorphisms in GDF9, FGF8, BMRP2 and LHCGR were significantly associated (P<0.01) with the number of oocytes collected by ovum pickup, whereas the SNP in the mtDNA was not. In addition, we estimated an allelic substitution effect of 1.13±0.01 (P<0.01) oocytes for the SNP in the FGF8 gene. The results we report herein provide further evidence to support the hypothesis that genetic variability is an important component of the number of antral follicles in the bovine ovary.


Sujet(s)
Bovins , Génome , Prélèvement d'ovocytes , Ovocytes/cytologie , Polymorphisme de nucléotide simple/physiologie , Animaux , Récepteurs de la protéine morphogénique osseuse de type II/génétique , Récepteurs de la protéine morphogénique osseuse de type II/métabolisme , Bovins/génétique , Bovins/physiologie , Numération cellulaire , Rendement/physiologie , Femelle , Facteur de croissance fibroblastique de type 10/génétique , Facteur de croissance fibroblastique de type 10/métabolisme , Facteur de croissance fibroblastique de type 8/génétique , Facteur de croissance fibroblastique de type 8/métabolisme , Études d'associations génétiques , Génome/génétique , Facteur-9 de croissance et de différenciation/génétique , Facteur-9 de croissance et de différenciation/métabolisme , Prélèvement d'ovocytes/médecine vétérinaire , Ovocytes/métabolisme , Follicule ovarique/métabolisme , Follicule ovarique/physiologie
19.
Reproduction ; 143(6): 815-23, 2012 Jun.
Article de Anglais | MEDLINE | ID: mdl-22457435

RÉSUMÉ

Fibroblast growth factors (FGFs) are involved in paracrine control of follicle development. It was previously demonstrated that FGF10 decreases estradiol (E(2)) secretion in granulosa cell culture and that theca cell FGF10 mRNA expression is decreased in healthy follicles from abattoir ovaries. The main objectives of this study were to evaluate FGF10 and FGFR2b mRNA expression during follicular development in vivo, to evaluate the effect of FGF10 on follicle growth using Bos taurus taurus cows as a model, and to gain more insight into the mechanisms through which FGF10 inhibits steroidogenesis. Messenger RNA encoding both FGF10 and FGFR2b (main FGF10 receptor) was significantly more expressed in subordinate follicles (SFs) than in dominant follicles (DFs). The intrafollicular injection of FGF10 into the largest growing follicle at 7-8 mm in diameter interrupted the DF growth in a dose-dependent manner (11±0.4, 8.3±1 and 5.9±0.3 mm for 0, 0.1, and 1 µg/ml FGF10, respectively, at 72 h after treatment; P<0.05). In a third experiment, follicles were obtained 24 h after FGF10 (1 µg/ml) or PBS treatment through ovariectomy. In theca cells, FGF10 treatment did not affect mRNA encoding steroidogenic enzymes, LHCGR and IGFBPs, but significantly upregulated FGF10 mRNA expression. The expression of CYP19A1 mRNA in granulosa cells was downregulated by FGF10 treatment, which was accompanied by a 50-fold decrease in E(2) production, and decreased cyclin D2 mRNA. These results have shown that FGF10 and its receptor FGFR2b are more expressed in SFs and provide solid in vivo evidence that FGF10 acts as an important regulator of follicular growth in cattle.


Sujet(s)
Bovins , Oestradiol/métabolisme , Facteur de croissance fibroblastique de type 10/pharmacologie , Follicule ovarique/effets des médicaments et des substances chimiques , Animaux , Bovins/génétique , Bovins/métabolisme , Bovins/physiologie , Relation dose-effet des médicaments , Régulation négative/effets des médicaments et des substances chimiques , Femelle , Facteur de croissance fibroblastique de type 10/administration et posologie , Facteur de croissance fibroblastique de type 10/génétique , Facteur de croissance fibroblastique de type 10/métabolisme , Expression des gènes/effets des médicaments et des substances chimiques , Cellules de la granulosa/effets des médicaments et des substances chimiques , Cellules de la granulosa/métabolisme , Cellules de la granulosa/physiologie , Microinjections , Ovogenèse/effets des médicaments et des substances chimiques , Ovogenèse/génétique , Ovogenèse/physiologie , Follicule ovarique/croissance et développement , Follicule ovarique/métabolisme , Follicule ovarique/physiologie , Récepteur FGFR2/génétique , Récepteur FGFR2/métabolisme , Cellules thécales/effets des médicaments et des substances chimiques , Cellules thécales/métabolisme , Cellules thécales/physiologie
20.
Theriogenology ; 77(9): 1779-87, 2012 Jun.
Article de Anglais | MEDLINE | ID: mdl-22365701

RÉSUMÉ

Oocyte meiotic resumption is triggered by the ovulatory gonadotropin surge; in cattle, angiotensin II (AngII) and prostaglandins (PG) are key mediators of this gonadotropin-induced event. Here, we tested the hypothesis that progesterone (P(4)) is also involved in oocyte meiotic resumption induced by the gonadotropin surge. In Experiment I, P(4) induced nuclear maturation in a dose-dependent manner using a coculture of follicular hemisections and cumulus-oocyte complexes. In the second experiment, using an in vivo model, an injection of mifepristone (MIFE; P(4) receptor antagonist) at the antrum of preovulatory follicles prevented GnRH-induced oocyte meiotic resumption in vivo. In Experiment III (coculture system similar to that of Experiment I), MIFE prevented stimulatory effects of AngII on resumption of meiosis, but saralasin (AngII receptor antagonist) did not inhibit P(4) actions. In Experiments IV and V, fibroblast growth Factor 10 (FGF10; known to suppress steroidogenesis in granulosa cells), blocked AngII-but not P(4)-induced oocyte meiotic resumption. Therefore, we inferred that AngII is upstream to P(4) in a cascade to induce meiotic resumption. Previously, we had reported that AngII acted throughout the PGs pathway to modulate nuclear progression. In Experiment V, indomethacin inhibited resumption of meiosis induced by P(4), providing further support to the AngII-P(4) sequential effect on meiotic resumption. In conclusion, we inferred that AngII, P(4) and PGs are sequential steps in the same pathway that culminates with bovine oocyte maturation.


Sujet(s)
Angiotensine-II/métabolisme , Bovins/sang , Techniques de maturation in vitro des ovocytes/médecine vétérinaire , Ovocytes/physiologie , Progestérone/métabolisme , Prostaglandines/métabolisme , Animaux , Facteur de croissance fibroblastique de type 10/pharmacologie , Indométacine/pharmacologie , Lutéolytiques/pharmacologie , Méiose/physiologie , Mifépristone/pharmacologie , Récepteurs à la progestérone/antagonistes et inhibiteurs
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE